Related Experiment Video
Updated: Jul 6, 2025
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Network targeting combination therapy of synthetic lethal vulnerabilities in 9p21-deficient glioblastoma: A case
Michael P Castro1,2,3, Kristin Dittmar4
1Department of Oncology, Personalized Cancer Medicine, PLLC, Los Angeles, California, USA.
Background:
Patients with relapsed or progressive glioblastoma only rarely respond to salvage therapies. Nevertheless, comprehensive genomic profiling can provide insight that can identify promising approaches. Signaling pathway analyses have revealed synthetic lethal partnerships, which create the possibility of targeting vulnerabilities arising from the loss of tumor suppressor genes. For synthetic lethal vulnerabilities that are not present in normal tissues, lethal cytotoxicity against cancer cells can be achieved without the necessity of causing normal tissue toxicity. This case report describes a patient with progressive glioblastoma with homozygous deletion of chromosome 9p21.
Methods And Results:
Vulnerabilities created by CDKN2A and MTAP loss were exploited with pemetrexed, bevacizumab, and candesartan to achieve a clinically meaningful remission by targeting multiple synthetic lethal nodes.
Conclusion:
Synthetic lethality can reveal the basis for exceptional responsiveness, thus extending the utility of molecular profiling and fulfilling the promise of precision medicine.
Insights
This study highlights how targeting synthetic lethal vulnerabilities, like those from CDKN2A and MTAP loss in glioblastoma, can lead to significant patient remission. This approach offers a promising avenue for precision medicine in treating aggressive brain tumors.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Glioblastoma relapse and progression show limited response to salvage therapies.
- Comprehensive genomic profiling identifies potential therapeutic targets.
- Synthetic lethality exploits tumor suppressor gene loss for targeted cancer cell death.
Purpose of the Study:
- To describe a glioblastoma patient with a homozygous deletion of chromosome 9p21.
- To investigate the therapeutic potential of targeting synthetic lethal vulnerabilities in this patient.
Main Methods:
- Genomic profiling to identify tumor vulnerabilities.
- Exploiting CDKN2A and MTAP loss-associated synthetic lethality.
- Administering pemetrexed, bevacizumab, and candesartan.
Main Results:
- Achieved a clinically meaningful remission in the patient.
- Demonstrated successful targeting of multiple synthetic lethal nodes.
- Showcased the efficacy of combination therapy in a rare genetic context.
Conclusions:
- Synthetic lethality can explain exceptional treatment responses.
- Molecular profiling is crucial for identifying precision medicine strategies.
- Targeting synthetic lethal nodes offers a promising approach for glioblastoma treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy